Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.75 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997641 | 0.87 | EPHX2 (0.73) | EPHX2EPHX1RAB9AALDH1A1 | |
| SCHEMBL4017201 | 0.87 | EPHX2 (0.76) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL13768765 | 0.86 | EPHX2 (0.72) | EPHX2EPHX1RAB9A | |
| SCHEMBL14072843 | 0.86 | EPHX2 (0.74) | EPHX2EPHX1NPC1RAB9A | |
| SCHEMBL2718374 | 0.86 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL1425023 | 0.85 | EPHX2 (0.74) | EPHX2EPHX1NPC1RAB9A | |
| SCHEMBL5000909 | 0.85 | EPHX2 (0.74) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL17560246 | 0.83 | MAPT (0.63) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL4010884 | 0.83 | CA12 (0.69) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL14984060 | 0.83 | EPHX2 (0.76) | EPHX2EPHX1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132176-A1 | 4-PIPERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | claimed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2008112022-A1 | 4 -PI PERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2008112022-A1 | 4 -PI PERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | EPHX2 5/4885EPHX1 1/4885NPC1 1529/4885 |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EPHX1 1/4885NPC1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.